Shipp MA - Search Results

1

Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.

Griffin GK, Weirather JL, Roemer MGM, Lipschitz M, Kelley A, Chen PH, Gusenleitner D, Jeter E, Pak C, Gjini E, Chapuy B, Rosenthal MH, Xu J, Chen BJ, Sohani AR, Lovitch SB, Abramson JS, Ishizuka JJ, Kim AI, Jacobson CA, LaCasce AS, Fletcher CD, Neuberg D, Freeman GJ, Hodi FS, Wright K, Ligon AH, Jacobsen ED, Armand P, Shipp MA, Rodig SJ. Griffin GK, et al. Among authors: shipp ma. Blood. 2021 Mar 11;137(10):1353-1364. doi: 10.1182/blood.2020006464. Blood. 2021. PMID: 32871584 Free PMC article.

2

CD10/NEP is expressed on Thy-1low B220+ murine B-cell progenitors and functions to regulate stromal cell-dependent lymphopoiesis.

Salles G, Chen CY, Reinherz EL, Shipp MA. Salles G, et al. Among authors: shipp ma. Blood. 1992 Oct 15;80(8):2021-9. Blood. 1992. PMID: 1382716 Free article.

3

Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele.

Ernst TJ, Gazdar A, Ritz J, Shipp MA. Ernst TJ, et al. Among authors: shipp ma. Blood. 1988 Oct;72(4):1163-7. Blood. 1988. PMID: 3048435 Free article.

4

Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies.

Salles G, Zain M, Jiang WM, Boussiotis VA, Shipp MA. Salles G, et al. Among authors: shipp ma. Blood. 1993 Dec 15;82(12):3539-47. Blood. 1993. PMID: 7505117 Free article.

5

Analysis of the human CD10/neutral endopeptidase 24.11 promoter region: two separate regulatory elements.

Ishimaru F, Shipp MA. Ishimaru F, et al. Among authors: shipp ma. Blood. 1995 Jun 1;85(11):3199-207. Blood. 1995. PMID: 7756651 Free article.

6

Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease?

Shipp MA. Shipp MA. Blood. 1994 Mar 1;83(5):1165-73. Blood. 1994. PMID: 8118021 Free article. Review.

7

High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.

Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. Shipp MA, et al. J Clin Oncol. 1995 Dec;13(12):2916-23. doi: 10.1200/JCO.1995.13.12.2916. J Clin Oncol. 1995. PMID: 8523055

8

CD10/neutral endopeptidase 24.11 is phosphorylated by casein kinase II and coassociates with other phosphoproteins including the lyn src-related kinase.

Ganju RK, Shpektor RG, Brenner DG, Shipp MA. Ganju RK, et al. Among authors: shipp ma. Blood. 1996 Dec 1;88(11):4159-65. Blood. 1996. PMID: 8943850 Free article.

9

Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.

Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA. Janicek M, et al. Among authors: shipp ma. J Clin Oncol. 1997 Apr;15(4):1631-7. doi: 10.1200/JCO.1997.15.4.1631. J Clin Oncol. 1997. PMID: 9193363

10

A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-Hodgkin's lymphoma.

Yakushijin Y, Steckel J, Kharbanda S, Hasserjian R, Neuberg D, Jiang W, Anderson I, Shipp MA. Yakushijin Y, et al. Among authors: shipp ma. Blood. 1998 Jun 1;91(11):4282-91. Blood. 1998. PMID: 9596677 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

181 results

Search Page